Advertisement
Advertisement
CEL-SCI Corporation (CVM)
NYSE American - Nasdaq Real Time Price. Currency in USD
Follow
As of 12:21PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 2.3200 |
| Open | 2.3000 |
| Bid | 2.2700 x 900 |
| Ask | 2.2800 x 1400 |
| Day's Range | 2.2550 - 2.3599 |
| 52 Week Range | 1.8800 - 6.1400 |
| Volume | |
| Avg. Volume | 130,849 |
| Market Cap | 99.625M |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8750 |
| Earnings Date | May 15, 2023 - May 19, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Aug 28, 1996 |
| 1y Target Est | 14.50 |
- Business Wire
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
VIENNA, Va., March 08, 2023--CEL-SCI’s Multikine Phase 3 cancer study shows 43% survival extension.
- Business Wire
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
VIENNA, Va., March 03, 2023--CEL-SCI to present new Phase 3 data at European Congress on Head & Neck Oncology.
- Zacks Small Cap Research
CVM: BLA Filing Still on the Horizon
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT First Quarter Fiscal Year 2023 Update CEL-SCI Corporation (NYSE:CVM) reported first quarter fiscal year 2023 results on February 15, 2023 and filed its Form 10-Q with the SEC. The company has continued to compile the clinical documentation necessary to support a Biologic License Application (BLA), which will be submitted in
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
